Los Angeles Capital Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,467
| Closed | -$234K | – | 1258 |
|
|
2024
Q2 | $234K | Sell |
10,467
-6,982
| -40% | -$156K | ﹤0.01% | 1091 |
|
|
2024
Q1 | $480K | Buy |
17,449
+5,754
| +49% | +$158K | ﹤0.01% | 881 |
|
|
2023
Q4 | $357K | Buy |
11,695
+422
| +4% | +$12.9K | ﹤0.01% | 962 |
|
|
2023
Q3 | $356K | Buy |
11,273
+294
| +3% | +$9.3K | ﹤0.01% | 915 |
|
|
2023
Q2 | $448K | Buy |
10,979
+1,078
| +11% | +$44K | ﹤0.01% | 886 |
|
|
2023
Q1 | $369K | Sell |
9,901
-762
| -7% | -$28.4K | ﹤0.01% | 950 |
|
|
2022
Q4 | $372K | Sell |
10,663
-1,280
| -11% | -$44.7K | ﹤0.01% | 975 |
|
|
2022
Q3 | $668K | Buy |
11,943
+1,301
| +12% | +$72.8K | ﹤0.01% | 833 |
|
|
2022
Q2 | $551K | Buy |
10,642
+767
| +8% | +$39.7K | ﹤0.01% | 934 |
|
|
2022
Q1 | $718K | Sell |
9,875
-1,050
| -10% | -$76.3K | ﹤0.01% | 892 |
|
|
2021
Q4 | $1.29M | Sell |
10,925
-101
| -0.9% | -$11.9K | ﹤0.01% | 634 |
|
|
2021
Q3 | $1.48M | Buy |
11,026
+1,106
| +11% | +$148K | 0.01% | 609 |
|
|
2021
Q2 | $1.61M | Sell |
9,920
-600
| -6% | -$97.1K | 0.01% | 648 |
|
|
2021
Q1 | $844K | Sell |
10,520
-16,025
| -60% | -$1.29M | ﹤0.01% | 973 |
|
|
2020
Q4 | $1.44M | Sell |
26,545
-600
| -2% | -$32.6K | 0.01% | 781 |
|
|
2020
Q3 | $540K | Buy |
27,145
+225
| +0.8% | +$4.48K | ﹤0.01% | 1048 |
|
|
2020
Q2 | $566K | Sell |
26,920
-350
| -1% | -$7.36K | ﹤0.01% | 1064 |
|
|
2020
Q1 | $334K | Buy |
+27,270
| New | +$334K | ﹤0.01% | 1022 |
|